Over 85 per cent of skin and eyelid inflammation patients also suffer from inflammatory ocular conditions, such as meibomian gland dysfunction (MGD), blepharitis, eyelid inflammation and eyelid telangiectasia.¹
Lumenis invites you to think outside the eye and offer your patients a solution to their skin related problems with M22 Optima IPL. When using IPL on your patient’s facial skin, especially in vicinity to the eyelids, efficacy and safety are essential. Optima IPL technology, developed by Lumenis, is unique to Lumenis M22.
It can be used to treat 20 different skin indications, including rosacea and other skin inflammatory conditions.²
1. Viso E, Millán AC, and Rodríguez-Ares MT, Rosacea-associated meibomian gland dysfunction – an epidemiological perspective, Eur Ophthalmol Rev, 2014; 8(1):13-16.
2. Weinkle AP, Doktor V, Emer J., Update on the Management of Rosacea, Clin Cosmet Investig Dermatol, 2015; 8:159-77.